Trial Profile
Safety and efficacy of brentuximab vedotin (BV) as monotherapy or in combination with bendamustine (BV-B) in relapsed refractory classic hodgkin lymphoma (CHL).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2017
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 27 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology